BR112022016746A2 - Sais e formas cristalinas de um agonista de taar1 - Google Patents

Sais e formas cristalinas de um agonista de taar1

Info

Publication number
BR112022016746A2
BR112022016746A2 BR112022016746A BR112022016746A BR112022016746A2 BR 112022016746 A2 BR112022016746 A2 BR 112022016746A2 BR 112022016746 A BR112022016746 A BR 112022016746A BR 112022016746 A BR112022016746 A BR 112022016746A BR 112022016746 A2 BR112022016746 A2 BR 112022016746A2
Authority
BR
Brazil
Prior art keywords
taar1
crystalline forms
salts
taar1 agonist
agonist
Prior art date
Application number
BR112022016746A
Other languages
English (en)
Portuguese (pt)
Inventor
Andrea Graeser Kirsten
Schwitter Urs
Stowasser Frank
Nicole Antoinette Tixeront Florence
Trussardi René
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112022016746A2 publication Critical patent/BR112022016746A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
BR112022016746A 2020-03-19 2021-03-17 Sais e formas cristalinas de um agonista de taar1 BR112022016746A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20164069 2020-03-19
PCT/EP2021/056749 WO2021185878A1 (en) 2020-03-19 2021-03-17 Salts and crystalline forms of a taar1 agonist

Publications (1)

Publication Number Publication Date
BR112022016746A2 true BR112022016746A2 (pt) 2022-10-11

Family

ID=69846246

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022016746A BR112022016746A2 (pt) 2020-03-19 2021-03-17 Sais e formas cristalinas de um agonista de taar1

Country Status (13)

Country Link
US (1) US12692256B2 (cg-RX-API-DMAC7.html)
EP (1) EP4121428B1 (cg-RX-API-DMAC7.html)
JP (2) JP2023517729A (cg-RX-API-DMAC7.html)
KR (1) KR20220155575A (cg-RX-API-DMAC7.html)
CN (1) CN115279752A (cg-RX-API-DMAC7.html)
AU (1) AU2021238632A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022016746A2 (cg-RX-API-DMAC7.html)
CA (1) CA3166331A1 (cg-RX-API-DMAC7.html)
ES (1) ES3044409T3 (cg-RX-API-DMAC7.html)
IL (1) IL294301A (cg-RX-API-DMAC7.html)
MX (1) MX2022010794A (cg-RX-API-DMAC7.html)
TW (1) TWI874616B (cg-RX-API-DMAC7.html)
WO (1) WO2021185878A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119654138A (zh) * 2022-08-12 2025-03-18 豪夫迈·罗氏有限公司 包含5-乙基-4-甲基-n-[4-[(2s)吗啉-2-基]苯基]-1h-吡唑-3-甲酰胺的药物组合物
TW202444712A (zh) * 2023-04-28 2024-11-16 大陸商江蘇豪森藥業集團有限公司 一種嗎啉雜環類化合物的鹽及其製備方法和應用
CN117903050B (zh) * 2024-03-15 2024-05-17 中国药科大学 阿立哌唑共晶及其药物组合物和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
RS60825B1 (sr) * 2016-03-17 2020-10-30 Hoffmann La Roche Aktivnost derivata 5-etiol-4-metil-pirazol-3-karboksamida kao agonista taar-a

Also Published As

Publication number Publication date
EP4121428B1 (en) 2025-08-13
EP4121428C0 (en) 2025-08-13
WO2021185878A1 (en) 2021-09-23
US20230120311A1 (en) 2023-04-20
MX2022010794A (es) 2022-09-27
TWI874616B (zh) 2025-03-01
CN115279752A (zh) 2022-11-01
KR20220155575A (ko) 2022-11-23
US12692256B2 (en) 2026-07-28
CA3166331A1 (en) 2021-09-23
JP2025166092A (ja) 2025-11-05
TW202140466A (zh) 2021-11-01
AU2021238632A1 (en) 2022-07-14
ES3044409T3 (en) 2025-11-26
EP4121428A1 (en) 2023-01-25
JP2023517729A (ja) 2023-04-26
IL294301A (en) 2022-08-01

Similar Documents

Publication Publication Date Title
AR066420A1 (es) Composicion farmaceutica suministrable oronasofaringeamente para la prevencion alivio / y o tratamiento de trastornos de miembros inquietos. uso.
CO2023013050A2 (es) Composiciones de psilocibina, métodos para prepararlas y métodos de uso de estas
CU23808B7 (es) Formas de presentación farmacéutica sólidas de administración oral con liberación rápida de principio activo
BR112022022669A2 (pt) Inibidores de nek7 quinase
BR112019003811A2 (pt) composição farmacêutica, método para aumentar os níveis plasmáticos de antagonista do receptor de nmda em um sujeito que precisa do mesmo, método para tratar uma doença ou transtorno em um sujeito que precisa do mesmo e uso da composição
BRPI0415953B8 (pt) formulação de dosagem de liberação controlada e conjunto de formas de dosagem de liberação controlada
BR112021023770A2 (pt) Compostos de derivado de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos
BR112013006030A2 (pt) composto e sais, solvatos, n-óxidos ou prodrogas farmaceuticamente aceitáveis, composição farmacêutica, uso do composto, kit, método de tratamento de uma doença, e, composição anti-helmíntica
BRPI0708071A8 (pt) Derivados de catecolamina deuterada e medicamentos compreendendo os ditos compostos
AR117655A1 (es) Composición farmacéutica para administración oral que comprende derivado de aminopirimidina o su sal
BR112023019435A2 (pt) Inibidores de nek7
BR112021009078A8 (pt) Antagonistas substituídos de receptor de adenosina de aminotriazolopirimidina e aminotriazolopirazina, composições farmacêuticas e seus usos
MX2023006751A (es) Nuevo derivado de camptotecina, composicion que comprende el mismo y su uso.
BRPI0618479A2 (pt) pirrolpiridinas composição farmacêutica que as contém
BRPI0920605A8 (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, método para o tratamento ou profilaxia de infecção pelo hiv ou para o tratamento, profilaxia, ou retardo no início ou progressão da aids em um paciente em necessidade deste.
BR112023007912A2 (pt) Formas cristalinas de um composto inibidor de kras g12c
MX2022010794A (es) Sales y formas cristalinas de un agonista del receptor 1 asociado a aminas traza (taar1).
BR112021024380A2 (pt) Formulações de liberação modificadas e usos das mesmas
PE20221455A1 (es) Composicion farmaceutica que comprende selexipag
CO2024015586A2 (es) Compuesto de sal de amonio cuaternario cíclico, método de preparación para el mismo y uso del mismo
CL2020000601A1 (es) Composición farmacéutica.
PE20070521A1 (es) 7-[2-[4-(6-FLUORO-3-METIL-1,2-BENCISOXAZOL-5-IL)-1-PIPERAZINIL]ETIL]-2-(1-PROPINIL)-7H-PIRAZOL-[4,3-E]-[1,2,4]-TRIAZOL-[1,5-C]-PIRIMIDIN-5-AMINA COMO ANTAGONISTA DEL RECEPTOR DE ADENOSINA A2a
BR112023021146A2 (pt) Compostos cristalinos de antagonistas do receptor muscarínico de acetilcolina m1
BRPI0923373B8 (pt) composições farmacêuticas compreendendo uma combinação de insulina com derivados de triazina, e uso da dita combinação
BR112018073743A2 (pt) composto, processo, método para tratamento de infecção bacteriana em um sujeito, uso de um composto, e composições farmacêuticas

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]